Imaging for Heart Failure Prevention in Diabetes Patients May Be Cost-Effective
Imaging to guide primary heart failure prevention in older asymptomatic patients with type 2 diabetes may be cost-effective
ACC Meeting Highlights
Sudden Cardiac Death Risk Factors Identified for Patients With Diabetes
Patients with sudden cardiac death, compared with those patients who did not die, were more likely to be older, have had diabetes for a longer duration, be on insulin, and have a higher baseline HbA1c.
Remnant Cholesterol Can Predict Coronary Artery Disease Events
Remnant cholesterol predicted coronary artery disease events univariately among patients with diabetes and without, even after adjustment for presence and extent of baseline disease.
Lung Impedance-Guided Therapy Reduced All-Cause and Heart Failure Mortality
Lung impedance-guided preemptive therapy of chronic heart failure reduced acute heart failure hospitalizations and cardiovascular and all-cause mortality.
VIDEO: Major Bleeding in Patients with Atrial Fibrillation and Diabetes Taking Rivaroxaban
W. Frank Peacock, IV, MD, discusses the risk of major bleeding among patients with atrial fibrillation and diabetes who are receiving rivaroxaban.
Aliskiren/Enalapril Combination Therapy Led to More Adverse Events in Chronic Heart Failure
The addition of aliskiren to enalapril led to more adverse events in patients with chronic heart failure without an increase in benefit.
Ixmyelocel-T Cell-Based Therapy Reduced Cardiac Events in Heart Failure
Ixmyelocel-T therapy reduced clinical cardiac events and improved patient outcomes.
Vagus Nerve Stimulation Device Did Not Reduce Heart Failure Hospitalization or Mortality Rates
While the vagus nerve stimulating device did not reduce hospitalization or mortality rates, it did improve walking distance, New York Heart Association class, and left ventricular end systolic volume index.
Hospital Stay, Complications Similar for Rate vs Rhythm Control in Post-Op Atrial Fibrillation
Rate vs rhythm control for postoperative atrial fibrillation yieled no statistically significant differences in adverse events or death.
Novel Compound CMX-2043 Did Not Reduce Contrast-Induced Acute Kidney Injury
CARIN trial reported no significant differences in acute kidney injury incidence between novel compound CMX-2043 and placebo.
Want to read more?
Please login or register first to view this content.
Next post in ACC Meeting Highlights
